About our research:

Oslo Myeloma Center is the largest center for clinical myeloma research in the Nordics. In 2017, 84 patients were enrolled in eleven clinical studies, in young and elderly, in newly diagnosed and in patients with one or multiple relapses, and in both phase 1, phase 2 and phase 3 studies. We collaborate with basal and translational research groups, especially with the KG Jebsen center for B cell malignancies at our hospital, with projects in drug-sensitivity screening, pathophysiology and immune therapy. In addition, we have a myeloma registry with both prospective and retrospective data. 


Back row from left: Liv Sigrun Eide, Kristin Låstad, Sylvia Rognli, Ann Døli, Anna Lysén, Anita Husøy, Marrydith Tran
Front row from left: Nina Gulbrandsen, Magnus Moksnes, Anne Carlsen, Puneet Kaur, Esther Morilla, Ulla Madsen, Fredrik Schjesvold, Larisa Myrseth


Ongoing trials:

  • Magnolia - Zoledronic acid 2 years vs 4 years
  • Panorama 3: Panobinostat-Velcade-Dexamethason randomized to different doses in relapse treatment
  • HOVON129 - Treatment of primary plasma cell leukemia
  • CA209-602: Elotuzumab, Nivolumab og Pomalidomid for >2 previous treatments
  • Melflufen vs Pomalidomide in relapsed myeloma
  • Cobimetinib +/- venetoclax +/- atezolizumab in relapsed myeloma
  • Carfilzomib and lenalidomide-based treatment for younger and elderly newly diagnosed primary plasma cell leukemia patients
  • Ixazomib vs Pomalidomide in relapsed myeloma
  • Venetoclax for patients with 11;14-translocation at relapse
  • Daratumumab vs observation in smouldering myeloma
  • KRd consolidation in myeloma patients with a positive PET-CT after standard first line treatment. A phase II study

Upcoming trials:

  • Ixazomib-Revlimid-Dexamethason in first line for the young
  • APO010 in drug sensitive relapsed myeloma
  • Phase-4-study on treatment with carfilzomib in routine practice